| P2093 | author name string | Bruce G Pollock | |
| | Francis E Lotrich | |
| | Charles F Reynolds Iii | |
| | Margaret Kirshner | |
| | Robert F Ferrell | |
| P2860 | cites work | Effectiveness of antidepressants. Meta-analysis of dose-effect relationships in randomised clinical trials | Q33758954 |
| | The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder | Q34227903 |
| | Serotonergic and noradrenergic reuptake inhibitors: prediction of clinical effects from in vitro potencies. | Q34295849 |
| | Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. | Q34317900 |
| | Effect of a triallelic functional polymorphism of the serotonin-transporter-linked promoter region on expression of serotonin transporter in the human brain | Q34481388 |
| | Genomic control, a new approach to genetic-based association studies | Q34539204 |
| | Analysis of association between the serotonin transporter and antidepressant response in a large clinical sample | Q34584111 |
| | Polymorphism of the serotonin transporter: implications for the use of selective serotonin reuptake inhibitors | Q34706797 |
| | Evidence that the SSRI dose response in treating major depression should be reassessed: a meta-analysis. | Q35063575 |
| | Time course of response to antidepressants in late-life major depression: therapeutic implications | Q35795147 |
| | Pharmacogenetics in the treatment of depression: pharmacodynamic studies | Q36110500 |
| | Initial conditions of psychotropic drug response: studies of serotonin transporter long promoter region (5-HTTLPR), serotonin transporter efficiency, cytokine and kinase gene expression relevant to depression and antidepressant outcome | Q36187462 |
| | Aging and clinical pharmacology: implications for antidepressants | Q36261418 |
| | Pharmacogenomics and antidepressant drugs | Q36438205 |
| | Relevance of assessing drug concentration exposure in pharmacogenetic and imaging studies | Q36511678 |
| | Candidate genes for antidepressant response to selective serotonin reuptake inhibitors | Q36718053 |
| | Concentration-response relationship in paroxetine treatment of diabetic neuropathy symptoms: a patient-blinded dose-escalation study. | Q39507635 |
| | Serum disposition of sertraline, N-desmethylsertraline and paroxetine: a pharmacokinetic evaluation of repeated drug concentration measurements during 6 months of treatment for major depression. | Q40496609 |
| | Patterns of antidepressant use in community practice | Q40717210 |
| | Relationship between brain serotonin transporter binding, plasma concentration and behavioural effect of selective serotonin reuptake inhibitors | Q43261539 |
| | Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity. | Q43722419 |
| | A twelve-week, double-blind, randomized comparison of nortriptyline and paroxetine in older depressed inpatients and outpatients | Q43819467 |
| | Initial conditions of serotonin transporter kinetics and genotype: influence on SSRI treatment trial outcome | Q43975771 |
| | Effect of nortriptyline and paroxetine on CYP2D6 activity in depressed elderly patients | Q44156712 |
| | Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression | Q44418347 |
| | 5-HTTLPR polymorphism of the serotonin transporter gene predicts non-remission in major depression patients treated with citalopram in a 12-weeks follow up study | Q44659875 |
| | Polymorphisms in the CYP 2D6 gene: association with plasma concentrations of fluoxetine and paroxetine | Q44669336 |
| | Paroxetine plasma levels: lack of correlation with efficacy or adverse events | Q44808218 |
| | Paroxetine in major depression: correlating plasma concentrations and clinical response | Q44893004 |
| | Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting | Q44914335 |
| | Effects of dosage and CYP2D6-mutated allele on plasma concentration of paroxetine | Q45045266 |
| | Effects of serotonin transporter promoter polymorphisms on serotonin function | Q45049144 |
| | Obesity among outpatients with major depressive disorder. | Q45054146 |
| | Neuroendocrine response to intravenous citalopram in healthy control subjects: pharmacokinetic influences | Q45057725 |
| | Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression | Q45134204 |
| | Utility of sparse concentration sampling for citalopram in elderly clinical trial subjects | Q45151684 |
| | Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism. | Q46423759 |
| | Paroxetine serum concentrations in depressed patients and response to treatment | Q46497971 |
| | Late-onset major depression: clinical and treatment-response variability | Q46602365 |
| | A computer algorithm for calculating the adequacy of antidepressant treatment in unipolar and bipolar depression | Q47669597 |
| | Fluoxetine and norfluoxetine plasma concentrations in major depression: a multicenter study | Q50948382 |
| | The human serotonin transporter gene polymorphism-basic research and clinical implications | Q59619248 |
| | Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine | Q60631126 |
| | Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression | Q73068042 |
| | Quantitative determination of paroxetine in plasma by high-performance liquid chromatography and ultraviolet detection | Q73453230 |
| | Brain kinetics of paroxetine and fluoxetine on the third day of placebo substitution: a fluorine MRS study | Q74241633 |
| | Population studies of polymorphisms of the serotonin transporter protein gene | Q74528498 |
| | Serum concentrations of fluvoxamine and clinical effects. A prospective open clinical trial | Q77614188 |
| | Maintenance treatment of major depression in old age | Q82843539 |
| | Long term efficacy of paroxetine in major depression: A study with plasma levels | Q88103328 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | serotonin | Q167934 |
| P304 | page(s) | 123-130 | |
| P577 | publication date | 2008-03-01 | |
| P1433 | published in | Journal of Psychiatry & Neuroscience | Q15814226 |
| P1476 | title | Serotonin transporter genotype interacts with paroxetine plasma levels to influence depression treatment response in geriatric patients | |
| P478 | volume | 33 | |